Subtype
Urinary System Adenocarcinoma
CI-CAN-00004181Explore in graph →
379 active trials17 approved drugs60 evidence items
- NCIt
- C224634
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004181Explore in graph →
Clinical trials
1,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (279)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02127710 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | completed | Phase 2 | 111 | AstraZenecaINDUSTRY | 4 | Apr 19, 2021 | clinicaltrials |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT00121251 |
| Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer |
| completed |
| Phase 1 / Phase 2 |
| 17 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Apr 6, 2021 |
| clinicaltrials |
| NCT02363751 | Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)(BEVABEL) | completed | Phase 2 | 36 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00827359 | Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT01835158 | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 157 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT00664326 | A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC | completed | Phase 2 | 49 | BayerINDUSTRY | 6 | Jan 29, 2021 | clinicaltrials |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04714697 | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 201 | Asan Medical CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT02853162 | Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)(ARREST) | terminated | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | unknown | Phase 2 | 8 | Kidney Cancer Research BureauOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01798446 | A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus | completed | Phase 2 | 41 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03066427 | Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.(INMUNOSUN) | completed | Phase 2 | 23 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01297244 | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 105 | AVEO Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 27, 2020 | clinicaltrials |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC(TAURUS) | terminated | Phase 2 | 58 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 27, 2020 | clinicaltrials |
| NCT00083941 | A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00325507 | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 173 | Tracon Pharmaceuticals Inc.INDUSTRY | 4 | Oct 19, 2020 | clinicaltrials |
| NCT00113217 | Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT00502307 | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | completed | Phase 2 | 272 | AVEO Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 1, 2020 | clinicaltrials |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma(PIVOT-RCC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Aug 13, 2020 | clinicaltrials |
| NCT04462445 | Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb(PIPELINE) | completed | Phase 2 | 25 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT03987698 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT00853372 | AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | completed | Phase 2 | 85 | AmgenINDUSTRY | 0 | Jul 1, 2020 | clinicaltrials |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | terminated | Phase 1 / Phase 2 | 24 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT02187302 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | completed | Phase 2 | 115 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT04146831 | Sintilimab in FH-deficient Renal Cell Carcinoma | unknown | Phase 2 | 37 | West China HospitalOTHER | 0 | May 12, 2020 | clinicaltrials |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | withdrawn | Phase 1 / Phase 2 | 0 | HealthPartners InstituteOTHER | 0 | May 7, 2020 | clinicaltrials |
| NCT01510119 | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01550367 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | completed | Phase 1 / Phase 2 | 30 | Leonard ApplemanOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00106301 | Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228 | completed | Phase 2 | 2 | CelgeneINDUSTRY | 2 | Nov 18, 2019 | clinicaltrials |
| NCT02700568 | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors(FavorAx) | completed | Phase 2 | 21 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03379012 | Testosterone in Metastatic Renal Cell Carcinoma Patients(FARETES) | completed | Phase 2 | 60 | Kidney Cancer Research BureauOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00106613 | A Research Study for Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | terminated | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2019 | clinicaltrials |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | terminated | Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2021source: clinicaltrials